PMID- 37542339
OWN - NLM
STAT- MEDLINE
DCOM- 20230807
LR  - 20231123
IS  - 2047-783X (Electronic)
IS  - 0949-2321 (Print)
IS  - 0949-2321 (Linking)
VI  - 28
IP  - 1
DP  - 2023 Aug 4
TI  - Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant 
      non-small cell lung cancer: a pooled analysis.
PG  - 267
LID - 10.1186/s40001-023-01219-y [doi]
LID - 267
AB  - BACKGROUND: The aim of this study was to evaluate the efficacy and safety of 
      osimertinib for the treatment of leptomeningeal metastases (LM) from epidermal 
      growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). METHODS: 
      We conducted a systematic review and meta-analysis to aggregate the clinical 
      outcomes of patients with LM from EGFR-mutant NSCLC treated with osimertinib. A 
      comprehensive literature search for published and unpublished studies was 
      implemented in April 2021 of PubMed, EMBASE, the Cochrane Library, and several 
      international conference databases, in accordance with the PRISMA guidelines. 
      Meta-analysis of proportions was conducted to calculate the pooled rate of 
      overall response rate (ORR), disease control rate (DCR), one-year overall 
      survival (OS), and adverse events (AEs). RESULTS: A total of eleven studies (five 
      prospective and six retrospective) including 353 patients were included. The 
      majority of patients (346/353, 98.0%) received osimertinib as >/= 2nd-line 
      treatment for LM, either at a dosage of 80 mg (161/353, 45.6%) or 160 mg 
      (191/353, 54.1%). The pooled rates of ORR and DCR were 42% (95% CI 24% to 59%) 
      and 93% (95% CI 88% to 97%), respectively. The pooled one-year OS rate was 59% 
      (95% CI 53% to 65%) in 233 patients from five studies. The highest incidence of 
      AEs of all grades was rash (53%), followed by diarrhea (45%), paronychia (35%), 
      decreased appetite (35%), and dry skin (27%), based on data from four studies. 
      CONCLUSIONS: Our study highlighted and confirmed the meaningful efficacy and a 
      manageable safety profile of osimertinib for the treatment of LM from EGFR-mutant 
      advanced NSCLC.
CI  - (c) 2023. BioMed Central Ltd., part of Springer Nature.
FAU - Wen, Lei
AU  - Wen L
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Zhen, Junjie
AU  - Zhen J
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Shan, Changguo
AU  - Shan C
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Lai, Mingyao
AU  - Lai M
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Hong, Weiping
AU  - Hong W
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Ye, Mingting
AU  - Ye M
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Yang, Yanying
AU  - Yang Y
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Li, Shaoqun
AU  - Li S
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Zhou, Zhaoming
AU  - Zhou Z
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
AD  - Department of Radiation Oncology, The First People's Hospital of Kashi 
      Prefecture, Kashi, China.
FAU - Zhou, Jiangfen
AU  - Zhou J
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Hu, Qingjun
AU  - Hu Q
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Li, Juan
AU  - Li J
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Tian, Xuwei
AU  - Tian X
AD  - Department of Radiation Oncology, The First People's Hospital of Kashi 
      Prefecture, Kashi, China.
FAU - Chen, Longhua
AU  - Chen L
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, 510515, People's Republic of China.
FAU - Cai, Linbo
AU  - Cai L
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
FAU - Xie, Zhanhong
AU  - Xie Z
AD  - State Key Laboratory of Respiratory Disease, National Clinical Research Center 
      for Respiratory Disease, Guangzhou Institute for Respiratory Health, The First 
      Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, People's 
      Republic of China. 13556184135@163.com.
FAU - Zhou, Cheng
AU  - Zhou C
AD  - Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China. 
      czhou.rob@gmail.com.
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, 510515, People's Republic of China. czhou.rob@gmail.com.
LA  - eng
GR  - No. A2020505/Medical Scientific Research Foundation of Guangdong Province/
GR  - No. A2020499/Medical Scientific Research Foundation of Guangdong Province/
GR  - No. B2021203/Medical Scientific Research Foundation of Guangdong Province/
GR  - No. B2021139/Medical Scientific Research Foundation of Guangdong Province/
GR  - No. 2019A1515011943/the Natural Science Foundation of Guangdong Province/
GR  - No. 2019M662974/China Postdoctoral Science Foundation/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230804
PL  - England
TA  - Eur J Med Res
JT  - European journal of medical research
JID - 9517857
RN  - 3C06JJ0Z2O (osimertinib)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Retrospective Studies
MH  - Prospective Studies
MH  - *Antineoplastic Agents/adverse effects
MH  - ErbB Receptors/genetics/therapeutic use
MH  - Protein Kinase Inhibitors/adverse effects
MH  - Mutation/genetics
PMC - PMC10403821
OTO - NOTNLM
OT  - EGFR
OT  - Efficacy
OT  - Leptomeningeal metastases (LM)
OT  - Meta-analysis
OT  - NSCLC
OT  - Osimertinib
COIS- The authors have declared no competing interests.
EDAT- 2023/08/05 05:42
MHDA- 2023/08/07 06:41
PMCR- 2023/08/04
CRDT- 2023/08/04 23:37
PHST- 2022/08/11 00:00 [received]
PHST- 2023/07/10 00:00 [accepted]
PHST- 2023/08/07 06:41 [medline]
PHST- 2023/08/05 05:42 [pubmed]
PHST- 2023/08/04 23:37 [entrez]
PHST- 2023/08/04 00:00 [pmc-release]
AID - 10.1186/s40001-023-01219-y [pii]
AID - 1219 [pii]
AID - 10.1186/s40001-023-01219-y [doi]
PST - epublish
SO  - Eur J Med Res. 2023 Aug 4;28(1):267. doi: 10.1186/s40001-023-01219-y.